Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Medical Technology Venture Partners (MedTech Venture Partners) focuses on funding and supporting medical technology entrepreneurs. Founded by a team with extensive experience in the medical device and diagnostics sector, the firm has overseen the conception, development, and launch of over 30 products. Their expertise spans clinical and regulatory environments, enabling them to provide critical support to early-stage companies.
Headquartered in Menlo Park, California, MedTech Venture Partners operates with a dedicated team that emphasizes hands-on operational expertise. The firm typically invests between $500,000 and $3 million in seed and Series A rounds, targeting companies that demonstrate advanced prototypes and strong bench and animal data. Their portfolio consists of ten companies, showcasing their commitment to the medical technology field.
MedTech Venture Partners invests primarily in novel therapeutic and diagnostic medical devices across the regulatory spectrum. Their investment strategy is centered on early-stage companies, particularly those at the seed or Series A stage. The firm seeks out businesses that have advanced prototypes and robust bench and animal data, indicating a strong potential for success in the market.
Investment checks range from $500,000 to $3 million, allowing them to support companies in their formative stages. While they are open to various stages of investment, their primary focus remains on early-stage ventures. MedTech Venture Partners also has the capacity to mobilize additional capital through their extensive network, enhancing their ability to support portfolio companies effectively.
MedTech Venture Partners has a diverse portfolio of ten companies, each contributing to advancements in medical technology:
Thomas Glanzmann: Partner at MedTech Venture Partners, brings extensive experience in the medical technology sector, focusing on operational support and strategic guidance for portfolio companies.
Radu Cautis: Partner & Managing Director, has a strong background in overseeing medical device development and regulatory compliance, contributing to the firm's investment strategy.
Peter Loescher: Partner, specializes in early-stage investments and has a track record of successful product launches in the medical technology field.
Regis Kelly: Venture Partner, offers insights from his extensive experience in the healthcare industry, enhancing the firm's strategic direction.
Christine Winoto: Venture Partner, brings expertise in clinical research and regulatory affairs, supporting portfolio companies in navigating complex environments.
Javad Seyedzadeh: Partner, focuses on identifying promising investment opportunities and providing operational support to portfolio companies.
Mathew Likens: Entrepreneur-in-Residence & Venture Partner, leverages his experience in launching medical devices to mentor founders and guide product development.
To pitch Medical Technology Venture Partners, founders should visit their website at medtechvp.com or email info@medtechvp.com. It is advisable to include a comprehensive deck that outlines the product, market opportunity, and team background. The firm values detailed information about clinical data and regulatory considerations.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review process.
On April 1, 2023, Medical Technology Venture Partners announced a new investment in Cala Health, a company developing wearable neuromodulation devices for chronic diseases. This investment aligns with their focus on innovative medical technologies.
In March 2023, the firm celebrated the acquisition of Novonate by Laborie, highlighting the successful exit of one of their portfolio companies. This acquisition underscores the firm's ability to identify and support companies with significant market potential.
Additionally, in February 2023, MedTech Venture Partners announced a follow-on investment in GT Medical Technologies, further solidifying their commitment to supporting companies that focus on targeted radiation therapy.
What investment criteria does Medical Technology Venture Partners look for?
MedTech Venture Partners focuses on early-stage companies in the medical technology sector, particularly those with advanced prototypes and strong bench and animal data. They typically invest in seed and Series A rounds.
How can I pitch to Medical Technology Venture Partners?
Founders can pitch their ideas by visiting the firm's website at medtechvp.com or by emailing info@medtechvp.com. It is recommended to include detailed information about the product, market potential, and team background in the pitch.
What makes Medical Technology Venture Partners different from other investors?
The firm distinguishes itself through its deep clinical and regulatory expertise, having overseen the launch of over 30 medical devices and diagnostics products. This hands-on operational support is a key value-add for portfolio companies.
What is the geographic focus of Medical Technology Venture Partners?
MedTech Venture Partners primarily invests in companies located in the United States, ensuring they can provide localized support and expertise.
What is the typical check size for investments?
The firm typically invests between $500,000 and $3 million in early-stage companies, allowing them to provide substantial support during critical growth phases.
What kind of post-investment involvement can founders expect?
MedTech Venture Partners offers hands-on operational expertise and deep clinical and regulatory knowledge, providing critical support beyond just capital. This involvement can include guidance on product development, regulatory pathways, and market entry strategies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.